Global Custom Market Research Reports Provider Company

phone

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) – Pipeline Review, H1 2018

  • Published Date: 06 Mar 2018
  • Number of Pages: 56
  • Category: Pharmaceuticals
  • Country: Global
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Pipeline Review, H1 2018

Summary

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 7 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Immunology which include indications Dyskinesia, Substance (Drug) Abuse, Chronic Pain, Neuropathic Pain, Pain, Acute Pain, Alcohol Addiction, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Inflammatory Pain, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, Parkinsons Disease, Post-Traumatic Stress Disorder (PTSD), Pulmonary Arterial Hypertension and Systolic Hypertension.

The latest report Nociceptin Receptor Pipeline Review, H1 2018, outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
- The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Publisher Name : Global Markets Direct
Introduction
Global Markets Direct Report Coverage
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Overview
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Companies Involved in Therapeutics Development
Blackthorn Therapeutics Inc
Grunenthal GmbH
Orexigen Therapeutics Inc
Serodus ASA
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drug Profiles
AT-076 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-089 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-127 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-200 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-212 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-326 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-403 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTRX-246040 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cebranopadol Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRT-6010 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OREX-1038 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize ORL1 for Acute Pain Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SER-100 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Dormant Products
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Discontinued Products
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Product Development Milestones
Featured News & Press Releases
Dec 07, 2017: BlackThorn Therapeutics Presents Preclinical and Clinical Data from Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting
Jul 24, 2017: BlackThorn Therapeutics Enrolls First Patient in Phase 2a Study of Lead Compound, BTRX-246040, in Major Depressive Disorder
Jul 10, 2017: Orexigen Announces Presentation of Preclinical Data for OREX-1038 at the International Narcotics Research Conference
Jan 05, 2017: Orexigen Therapeutics Provides Update on OREX-1038 at 35th Annual J.P. Morgan Healthcare Conference
Dec 19, 2016: Serodus: Novel article on SER100 in patients with isolated systolic hypertension is published in Journal of Clinical Pharmacology in Drug Development
Oct 25, 2016: Orphan drug designation for SER100 in Pulmonary Arterial Hypertension granted in U.S.
Sep 30, 2016: Grunenthals cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain
Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder
May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile
Apr 18, 2016: PCT SER100 patent application filed - Serodus demonstrates a novel mechanism of action in Pulmonary Hypertension
Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
Apr 20, 2015: Provisional patent application filed for the Orphan Diseases of Pulmonary Hypertension
Sep 15, 2014: Serodus announces details on the clinical study of SER100 in patients with systolic hypertension
Sep 09, 2014: Serodus Announces Positive Phase IIa Clinical Study Results On SER100 In Patients with Systolic Hypertension
Jun 23, 2014: Serodus Completes The Enrollment Of Patients In Phase IIa Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Blackthorn Therapeutics Inc, H1 2018
Pipeline by Grunenthal GmbH, H1 2018
Pipeline by Orexigen Therapeutics Inc, H1 2018
Pipeline by Serodus ASA, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Report Nociceptin Receptor-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nociceptin Receptor industry, standing on the readers perspective, delivering detailed market data and penetrating insights.

View Report

Report Nociceptin Receptor-India Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nociceptin Receptor industry, standing on the readers perspective, delivering detailed market data and penetrating insights. No

View Report

Report Nociceptin Receptor-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nociceptin Receptor industry, standing on the readers perspective, delivering detailed market data and penetrating insights. No

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports